standard superior - dofaq.co
standard superior

Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukemia, with 77% of patients progression free at three years in AMPLIFY Phase II

AstraZeneca US - 08 Dec 2024
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukemia, with 77% of patients progression free at three years in AMPLIFY Phase II  ...

What's New